The effect of cilostazol on vasospasm after subarachnoid hemorrhage: a role for spreading depolarization

The effect of cilostazol on vasospasm after subarachnoid hemorrhage: a role for spreading depolarization - The effect of cilostazol on vasospasm after subarachnoid hemorrhage

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008225

Enrollment

Registered

2012-08-01

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subarachnoid hemorrhage

Interventions

The patients of subarachnoid hemorrhage are treated with cilostazol after clipping/coi embolization of ruptured cerebral aneurysm. The patients of subarachnoid hemorrhage are not treated with cilostaz

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients after aneurysmal subarachnoid hemorrhage. The patients treated with surgical clipping or coil embolizaion within 72 hours after the onset of subarachnoid henorrhage.

Exclusion criteria

Exclusion criteria: The patients treated with surgical clipping or coil embolizaion after 72 hours of the onset of subarachnoid henorrhage.

Design outcomes

Primary

Measure	Time frame
Incidence of cerebral vasospasm in the cilostazol treated group.	—

Secondary

Measure	Time frame
Clinical outcome (The Modified Rankin Scale; mRS) 30 days and 90 days after the onset of the patients treated with cilostazol. Incidence of cerebral vasospasm detected on angiography. Cerebral microcirculation of patients treated with cilostazol.	—

Countries

Japan

Contacts

Public ContactSadahiro Nomura

Yamaguchi University School of Medicine Department of Neurosurgery and Clinical Neuroscience

shirao@yamaguchi-u.ac.jp0836-22-2295

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026